Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort

Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated C-Reactive Protein

(2018) Cory Trankle et al.   AMERICAN JOURNAL OF CARDIOLOGY

Inflammatory and Cholesterol Risk in the FOURIER Trial

(2018) Erin A. Bohula et al.   CIRCULATION

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

(2018) Aruna D. Pradhan et al.   CIRCULATION

Systemic inflammation and functional capacity in elderly heart failure patients

(2018) Sara Radenovic et al.   Clinical Research in Cardiology

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab

(2018) Paul M Ridker et al.   Journal of Clinical Lipidology

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

(2018) Paul M Ridker et al.   LANCET

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

(2018) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

From C-Reactive Protein to Interleukin-6 to Interleukin-1

(2016) Paul M Ridker   CIRCULATION RESEARCH

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Relationship of Cigarette Smoking With Inflammation and Subclinical Vascular DiseaseSignificance

(2015) John W. McEvoy et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCLINICAL PERSPECTIVES

(2015) Erin A. Bohula et al.   CIRCULATION

Innate Immunity and the Failing Heart

(2015) Douglas L. Mann   CIRCULATION RESEARCH

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study

(2014) A. C. Morton et al.   EUROPEAN HEART JOURNAL

Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome

(2014) Michelle L. O’Donoghue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-Inflammatory Activity of Ezetimibe by Regulating NF-κB/MAPK Pathway in THP-1 Macrophages

(2014) Li Qin et al.   PHARMACOLOGY

Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease

(2012) Stefan M. Nidorf et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells

(2010) Michihisa Jougasaki et al.   BRITISH JOURNAL OF PHARMACOLOGY

Ezetimibe and Vascular Inflammation

(2010) Toshiyuki Ishibashi et al.   Current Vascular Pharmacology

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Anti-inflammatory effects of the Mediterranean diet: the experience of the PREDIMED study

(2010) Ramon Estruch   PROCEEDINGS OF THE NUTRITION SOCIETY

Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes

(2009) Kausik K. Ray et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect

(2009) D Gómez-Garre et al.   BRITISH JOURNAL OF PHARMACOLOGY

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells

(2007) Karin Mausner-Fainberg et al.   ATHEROSCLEROSIS